Last reviewed · How we verify
HUMAN PAPILLOMAVIRUS, L1 PROTEIN VIRUS LIKE PARTICLES
At a glance
| Generic name | HUMAN PAPILLOMAVIRUS, L1 PROTEIN VIRUS LIKE PARTICLES |
|---|---|
| Modality | Vaccine component |
| Phase | FDA-approved |
| First approval | 2006 |
Approved indications
Common side effects
Key clinical trials
- A Study to Assess the Reduction of Human Papillomavirus (HPV) Viral Infectivity and Transmission in HPV-Positive Women After Vaccination With 9vHPV (RIFT-HPV) (PHASE4)
- Cervical Intraepithelial Neoplasm (CIN) in Women (Gardasil) (V501-015) (PHASE3)
- Efficacy Against Oral Persistent Infection, Immunogenicity and Safety of the 9-valent Human Papillomavirus Vaccine (9vHPV) in Men Aged 20-45 Years (V503-049) (PHASE3)
- Long-term Follow-up of Bivalent Human Papillomavirus (HPV) Vaccine Study in Women
- Evaluating the 2-dose Immunization Schedule of Human Papillomavirus (HPV)-16/18 in Adolescent Females (PHASE2)
- A Phase III Study of Human Papillomavirus (HPV)-16/18 Vaccine. (PHASE3)
- V501 Immunogenicity Study in Females Age 9 to 17 Years (V501-028) (PHASE2)
- Study to Test the Safety of HPV Vaccine in Women (V501-011)(COMPLETED) (PHASE3)
Primary sources
Every claim on this page is sourced from regulatory or scientific primary sources. See our editorial policy for full methodology.
| Source | Used for |
|---|---|
| FDA label | Mechanism, indications, dosing, boxed warnings, drug interactions |
| ClinicalTrials.gov | Trial enrolment, design, endpoints, results |
Competitive intelligence
For the full competitive landscape — auto-detected comparators, recent regulatory actions across the set, upcoming PDUFA, patent timeline, sponsor landscape:
- HUMAN PAPILLOMAVIRUS, L1 PROTEIN VIRUS LIKE PARTICLES CI brief — competitive landscape report
- HUMAN PAPILLOMAVIRUS, L1 PROTEIN VIRUS LIKE PARTICLES updates RSS · CI watch RSS